Market Overview - The Hong Kong stock market saw all major indices rise, with the Hang Seng Index up 0.13% to 25,928.08 points, the Hang Seng Tech Index up 0.11% to 5,618.36 points, and the Hang Seng China Enterprises Index up 0.04% to 9,162.37 points, with a total market turnover of HKD 207.08 billion [1] - Among the Hang Seng Index constituents, 51 stocks rose while 32 fell, with Meituan leading the blue-chip stocks with a 5.65% increase [1] Individual Stock Performance - Alibaba's stock saw a turnover of HKD 17.256 billion, down 1.90%, primarily due to a 72% year-on-year decline in adjusted net profit for Q2 of the fiscal year 2026 [2] - Meituan's stock had a turnover of HKD 13.327 billion, rising 5.65%, while Tencent Holdings experienced a turnover of HKD 8.976 billion, down 0.88% [2] Sector Performance - The healthcare sector index rose by 1.04%, while the telecommunications sector index increased by 0.52% [2] - The materials sector index fell by 1.09%, and the information technology sector index decreased by 0.58% [2] Meituan's Stock Movement - Meituan's stock surged by as much as 7.07% on November 25, closing at HKD 103.80 per share, following Alibaba's announcement to scale back its investment in Taobao Flash Sales, which positively impacted the food delivery competition landscape [3] - Meituan is expected to report its Q3 earnings on November 28, with market speculation suggesting it may face its first quarterly loss in over three years due to "irrational competition" eroding most of its profits for the quarter [3] Biotechnology Sector - The biotechnology sector has seen a rebound for the third consecutive day, with the Hang Seng Biotechnology Index rising by 1.25% [4] - Notable performers in the biotechnology sector include Kangfang Biotech, which rose by 3.97%, and Sanofi Biotech, which increased by 3.75% [7] Investment Trends in Healthcare - According to a report by CICC (Hong Kong), the global healthcare capital market has shown a recovery trend, with total financing in October reaching approximately USD 112 billion, marking a new high for the year [8] - The report highlights significant mergers and acquisitions in the medical device sector in October, indicating a focus on strategic core business enhancements and high-growth potential niche markets [9]